Search

Displaying results 31 - 40 of 81 in total
  1. Indication

    Invasive Breast Cancer

    go.drugbank.com/conditions/DBCOND0037365
    Drugs: Raloxifene · Tamoxifen
  2. Drug

    Letrozole

    go.drugbank.com/drugs/DB01006
    ApprovedInvestigational

    Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affe...

  3. Drug

    Ibuprofen

    go.drugbank.com/drugs/DB01050
    ApprovedInvestigational

    Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in ...

    Products: PROFEN K.B. TABLETS, PROFEN K.B. TABLETS 400
  4. Drug

    Thalidomide

    go.drugbank.com/drugs/DB01041
    ApprovedInvestigationalWithdrawn

    A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thal...

  5. Drug

    Panomifene

    go.drugbank.com/drugs/DB20726
    Experimental

    The usage of the INN stem '-mifene' in the name indicates that Panomifene is a antiestrogen, clomifene and tamoxifen derivative. Panomifene has a monoisotopic molecular weight of 427.18 Da.

  6. Drug

    Droloxifene

    go.drugbank.com/drugs/DB15641
    Experimental

    Droloxifene, a derivative of the triphenylethylene drug tamoxifen, is a novel selective estrogen receptor modulator (SERM). … Droloxifene also exhibits more rapid pharmacokinetics, reaching peak concentrations and being eliminated much more rapidly than tamoxifen.

  7. Drug

    Lormetazepam

    go.drugbank.com/drugs/DB13872
    Approved

    It is marketed by Auden Mckenzie (Pharma Division) in 0.5 and 1 mg tablet formulations.

  8. Drug

    Raloxifene

    go.drugbank.com/drugs/DB00481
    ApprovedInvestigational

    Compared to estrogen and tamoxifen, raloxifene was not associated with an increased risk of uterine cancer and it does not cause endometrial proliferation. … However, due to the off-target actions by HRT, newer non-hormonal agents such as raloxifene and [tamoxifen] have been developed to reduce adverse events through selective pharmacological actions on tissue-specific

  9. Indication

    Ovarian Cancer

    go.drugbank.com/conditions/DBCOND0028213
    Drugs: Dactinomycin · Epirubicin · Etoposide · Ifosfamide · Irinotecan · Paclitaxel +2 more
  10. Drug

    MLN0415

    go.drugbank.com/drugs/DB05183
    Experimental

    In preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins.